This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Allergan Reports Third Quarter 2012 Operating Results

Stocks in this article: AGN

Reporting sales performance using constant currency sales has the limitation of excluding currency effects from the comparison of sales results over various periods, even though the effect of changing foreign currency exchange rates has an actual effect on Allergan’s operating results. Investors should consider these effects in their overall analysis of Allergan’s operating results.

ALLERGAN, INC.
Condensed Consolidated Statements of Earnings and
Reconciliation of Non-GAAP Adjustments

(Unaudited)

 
    Nine months ended

In millions, except per share amounts

September 30, 2012       September 30, 2011
   

 

       

 

   
GAAP

Non-GAAP Adjustments

Non-GAAP GAAP

Non-GAAP Adjustments

Non-GAAP
Revenues
Product net sales $ 4,224.2 $ --   $ 4,224.2 $ 3,964.3 $ -- $ 3,964.3
Other revenues   73.0     --   73.0     52.5     --   52.5  
4,297.2 -- 4,297.2 4,016.8 -- 4,016.8
 
Operating costs and expenses

Cost of sales (excludes amortization of acquired intangible assets)

586.3

(0.4

)

(a)(b)

585.9

566.7

(0.4

)

(k)

566.3

Selling, general and administrative 1,710.5 (26.4

)

(b)(c)(d)(e)

1,684.1 1,694.7

(80.4

)

(l)(m)(n)(o)(p)

1,614.3
Research and development 750.3 (62.8

)

(d)(e)

687.5 676.4

(45.0

)

(n)

631.4
Amortization of acquired intangible assets 98.1 (80.4

)

(f)

17.7 95.6 (77.9

)

(f)

17.7
Impairment of intangible assets and related costs -- -- -- 23.7

(23.7

)

(o)(q)(r)

--
Restructuring charges   4.7     (4.7

)

(g)

  --     4.6     (4.6

)

(g)

  --  
 
Operating income 1,147.3 174.7 1,322.0 955.1 232.0 1,187.1
 
Non-operating income (expense)
Interest income 4.8 -- 4.8 5.6 -- 5.6
Interest expense (48.8 )

0.8

(h)

(48.0 ) (55.1 )

7.3

(s)

(47.8 )
Other, net   (19.3 )  

15.2

(i)

  (4.1 )   10.4  

(13.4

)

(t)(u)

  (3.0 )
  (63.3 )   16.0

 

  (47.3 )   (39.1 )   (6.1

)

 

  (45.2 )
 
Earnings before income taxes 1,084.0 190.7 1,274.7 916.0 225.9 1,141.9
 
Provision for income taxes   306.7    

44.2

(j)

  350.9     257.6  

59.9

(v)

  317.5  
 
Net earnings 777.3 146.5

923.8

658.4 166.0 824.4
 
Net earnings attributable to noncontrolling interest   2.7     --   2.7     3.7     --   3.7  
 
Net earnings attributable to Allergan, Inc. $ 774.6   $ 146.5 $ 921.1   $ 654.7   $ 166.0 $ 820.7  
 
Net earnings per share attributable to

Allergan, Inc. stockholders:

Basic $ 2.56   $ 3.05   $ 2.15   $ 2.70  
Diluted $ 2.52   $ 2.99   $ 2.11   $ 2.64  
 
Weighted average number of common

shares outstanding:

Basic

302.1

 

302.1

304.4

 

304.4

Diluted

307.7

 

307.7

310.3

 

310.3
 

Selected ratios as a percentage of product net sales

 
Cost of sales (excludes amortization of acquired intangible assets)

13.9

%

13.9 %

14.3

%

14.3

%

Selling, general and administrative 40.5 % 39.9 % 42.7 % 40.7 %
Research and development 17.8 % 16.3 % 17.1 % 15.9 %
 
(a)       Fair market value inventory adjustment rollout of $0.3 million associated with the purchase of a distributor’s business in Russia related to Allergan’s products
(b) Expenses from changes in fair value of contingent consideration of $15.8 million and integration and transaction costs of $0.6 million associated with business combinations, consisting of cost of sales of $0.1 million and selling, general and administrative expenses of $0.5 million
(c) Aggregate charges of $8.9 million for external costs for stockholder derivative litigation associated with the DOJ settlement announced in September 2010 and other legal contingency expenses
(d) Expenses related to the realignment of various business functions and the restructuring of the obesity intervention business of $1.4 million, consisting of selling, general and administrative expenses of $1.1 million and research and development expenses of $0.3 million
(e) Upfront licensing fees of $62.5 million included in research and development expenses associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs of $0.1 million included in selling, general and administrative expenses
(f) Amortization of certain acquired intangible assets related to business combinations, asset acquisitions and product licenses
(g) Net restructuring charges
(h) Interest expense associated with changes in estimated taxes related to uncertain tax positions included in prior year filings
(i) Unrealized loss on the mark-to-market adjustment to derivative instruments
(j) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions):
    Tax effect
Non-GAAP pre-tax adjustments of $190.7 million $ (50.9 )
Change in estimated taxes related to uncertain tax positions included in prior year filings  

6.7

 
$ (44.2 )
(k)       Fair market value inventory adjustment rollout associated with the purchase of a distributor’s business in South Africa related to Allergan’s products
(l) Expenses from changes in fair value of contingent consideration of $2.3 million and integration and transaction costs of $1.5 million associated with business combinations
(m) External costs of $3.1 million for stockholder derivative litigation costs associated with the DOJ settlement announced in September 2010
(n) Upfront licensing fee of $45.0 million included in research and development expenses associated with a license and collaboration agreement with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs of $0.1 million included in selling, general and administrative expenses
(o)

Fixed asset impairment of $2.2 million and a gain of $9.4 million from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary included in selling, general and administrative expenses, and intangible asset impairment of $16.1 million resulting from the discontinued development of the Easyband TM Remote Adjustable Gastric Band System, a technology acquired by Allergan in the 2007 EndoArt SA acquisition

(p) Upfront payment of $60.0 million and subsequent milestone payment of $20.0 million for the FDA acceptance of an NDA filing for technology that has not achieved regulatory approval associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. and related transaction costs of $0.6 million
(q) Impairment of an in-process research and development asset related to a tissue reinforcement technology acquired in connection with the 2010 acquisition of Serica Technologies, Inc. of $4.3 million
(r)

Additional costs of $3.3 million for the termination of a third-party agreement primarily related to the promotion of Sanctura XR ® associated with the impairment of the Sanctura ® assets in the third quarter of 2010

(s) Non-cash interest expense associated with amortization of convertible debt discount
(t) Unrealized gain on the mark-to-market adjustment to derivative instruments of $12.0 million
(u) Gain on sale of investments of $1.4 million
(v) Total tax effect for non-GAAP pre-tax adjustments
 
ALLERGAN, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
 

in millions

    September 30,

2012

      December 31,

2011

 
Assets
 
Cash and equivalents $ 2,655.0 $ 2,406.1
Short-term investments 279.9 179.9
Trade receivables, net 872.6 730.6
Inventories 265.1 249.7
Other current assets   463.2     482.0  
 
Total current assets 4,535.8 4,048.3
 
Property, plant and equipment, net 822.8 807.0
Intangible assets, net 1,079.4 1,165.2
Goodwill 2,092.9 2,088.4
Other noncurrent assets   380.0     399.7  
 
Total assets $ 8,910.9   $ 8,508.6  
 
 
Liabilities and equity
 
Notes payable $ 40.7 $ 83.9
Accounts payable 210.6 200.4
Other accrued expenses and income taxes   803.6     670.7  
 
Total current liabilities 1,054.9 955.0
 
Long-term debt 1,515.5 1,515.4
Other liabilities 746.2 705.8
 
Equity:
Allergan, Inc. stockholders’ equity 5,569.6 5,309.6
Noncontrolling interest   24.7     22.8  
Total equity   5,594.3     5,332.4  
 
Total liabilities and equity $ 8,910.9   $ 8,508.6  
 
DSO 57 48
 
DOH 128 125
 
Cash and equivalents and short-term investments $ 2,934.9 $ 2,586.0
Total notes payable and long-term debt   (1,556.2 )   (1,599.3 )
Cash and equivalents and short-term investments, net of debt $ 1,378.7   $ 986.7  
 
Debt-to-capital percentage 21.8 % 23.1 %
 
ALLERGAN, INC.
Reconciliation of Non-GAAP Earnings and Diluted Earnings Per Share Attributable to Allergan, Inc. Stockholders
(Unaudited)
 

In millions, except per share amounts

      Three months ended

 

September 30,

2012

    September 30,

2011

 
Net earnings attributable to Allergan, Inc. $ 249.4 $ 249.8
 
Non-GAAP pre-tax adjustments:
Expenses from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

2.4

0.6

External costs for stockholder derivative litigation associated with the DOJ settlement 0.5 0.8
Expenses related to the realignment of various business functions and the restructuring of the obesity intervention business

0.6

--

Research and development expenses related to upfront licensing fees associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs

 

62.6

 

--

Amortization of acquired intangible assets 27.4 26.0
Net restructuring charges (reversal) 3.8 (0.1 )
Unrealized loss (gain) on derivative instruments 7.1 (16.8 )
Fair market value inventory adjustment rollout associated with the purchase of a distributor’s business in South Africa

--

0.4

Milestone payment for the FDA acceptance of an NDA filing for technology associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc.

--

20.0

Impairment of an in-process research and development asset related to a tissue reinforcement technology acquired in connection with the 2010 acquisition of Serica Technologies, Inc.

 

--

 

4.3

Gain on sale of investments   --     (0.5 )
353.8 284.5
 
Tax effect for above items (28.8 ) (10.2 )
Change in estimated tax benefit associated with the upfront licensing fee paid to Molecular Partners AG

--

11.7

Change in estimated taxes related to uncertain tax positions and tax credits included in prior year filings  

--

   

(1.9

)

Non-GAAP earnings attributable to Allergan, Inc. $ 325.0   $ 284.1  
 
Weighted average number of shares outstanding 300.1 304.2
 

Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price

 

 

5.2

   

 

5.6

 
  305.3     309.8  
 

Diluted earnings per share attributable to Allergan, Inc. stockholders

$ 0.82 $ 0.81
 
Non-GAAP earnings per share adjustments:
Expenses from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

0.01

--

Research and development expenses related to upfront licensing fees associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs

 

0.15

 

--

Amortization of acquired intangible assets 0.06 0.06
Net restructuring charges (reversal) 0.01 --
Unrealized loss (gain) on derivative instruments 0.01 (0.03 )
Milestone payment for the FDA acceptance of an NDA filing for technology associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc.

--

0.04

Impairment of an in-process research and development asset related to a tissue reinforcement technology acquired in connection with the 2010 acquisition of Serica Technologies, Inc.

 

--

 

0.01

Change in estimated tax benefit associated with the upfront licensing fee paid to Molecular Partners AG

--

0.04

Change in estimated taxes related to uncertain tax positions and tax credits included in prior year filings  

--

   

(0.01

)

 
Non-GAAP diluted earnings per share attributable to Allergan, Inc. stockholders $ 1.06   $ 0.92  
 
Year over year change 15.2 %
 
ALLERGAN, INC.
Reconciliation of Non-GAAP Earnings and Diluted Earnings Per Share Attributable to Allergan, Inc. Stockholders
(Unaudited)
 

In millions, except per share amounts

  Nine months ended

 

September 30,

2012

  September 30,

2011

 
Net earnings attributable to Allergan, Inc. $ 774.6 $ 654.7
 
Non-GAAP pre-tax adjustments:
Fair market value inventory adjustment rollout associated with the purchases of distributor businesses

0.3

0.4

Expenses from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

16.4

3.8

Aggregate charges for external costs for stockholder derivative litigation associated with the DOJ settlement and other legal contingency expenses

8.9

3.1

Expenses related to the realignment of various business functions and the restructuring of the obesity intervention business

1.4

--

Research and development expenses related to upfront licensing fees associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs

 

62.6

 

45.1

Amortization of acquired intangible assets 80.4 77.9
Net restructuring charges 4.7 4.6
Interest expense associated with changes in estimated taxes related to uncertain tax positions included in prior year filings

0.8

--

Unrealized loss (gain) on derivative instruments 15.2 (12.0 )
Cumulative net expense for fixed asset impairment, a gain from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary and intangible asset impairment resulting from the discontinued development of the Easyband TM Remote Adjustable Gastric Band System

 

 

--

 

 

8.9

Upfront payment and subsequent milestone payment for the FDA acceptance of an NDA filing for technology that has not achieved regulatory approval associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. and related transaction costs

 

 

--

 

 

80.6

Impairment of an in-process research and development asset related to a tissue reinforcement technology acquired in connection with the 2010 acquisition of Serica Technologies, Inc.

 

--

 

4.3

Additional costs for the termination of a third-party agreement primarily related to the promotion of Sanctura XR ®

--

3.3

Non-cash interest expense associated with amortization of convertible debt discount -- 7.3
Gain on sale of investments   --     (1.4 )
965.3 880.6
 
Tax effect for above items (50.9 ) (59.9 )
Change in estimated taxes related to uncertain tax positions included in prior year filings   6.7     --  
Non-GAAP earnings attributable to Allergan, Inc. $ 921.1   $ 820.7  
 
Weighted average number of shares outstanding 302.1 304.4
 

Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price

 

5.6

 

5.5

 
Dilutive effect of assumed conversion of convertible notes outstanding   --     0.4  
  307.7     310.3  
 
Diluted earnings per share attributable to Allergan, Inc. stockholders   $ 2.52 $ 2.11
 
Non-GAAP earnings per share adjustments:
Expenses from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

0.05

0.01

Aggregate charges for external costs for stockholder derivative litigation associated with the DOJ settlement and other legal contingency expenses

0.03

--

Research and development expenses related to upfront licensing fees associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs

 

0.15

 

0.13

Amortization of acquired intangible assets 0.18 0.17
Net restructuring charges 0.01 0.02
Unrealized loss (gain) on derivative instruments 0.03 (0.02 )
Cumulative net expense for fixed asset impairment, a gain from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary and intangible asset impairment resulting from the discontinued development of the Easyband TM Remote Adjustable Gastric Band System

 

 

--

 

 

0.03

Upfront payment and subsequent milestone payment for the FDA acceptance of an NDA filing for technology that has not achieved regulatory approval associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. and related transaction costs

 

 

--

 

 

0.16

Impairment of an in-process research and development asset related to a tissue reinforcement technology acquired in connection with the 2010 acquisition of Serica Technologies, Inc.

 

--

 

0.01

Additional costs for the termination of a third-party agreement primarily related to the promotion of Sanctura XR ®

--

0.01

Non-cash interest expense associated with amortization of convertible debt discount -- 0.01
Change in estimated taxes related to uncertain tax positions included in prior year filings  

0.02

 

--

 
 
Non-GAAP diluted earnings per share attributable to Allergan, Inc. stockholders $ 2.99 $ 2.64  
 
Year over year change 13.3 %
 
ALLERGAN, INC.
Supplemental Non-GAAP Information
(Unaudited)
 
     

  Three months ended

                       

 September 30,

   

September 30,

$ change in net sales

Percent change in net sales

  2012

   2011

  Total

  Performance

   Currency

   Total

  Performance

Currency

in millions

Eye Care Pharmaceuticals $ 663.2 $ 611.6 $ 51.6 $ 76.2 $ (24.6 ) 8.4 % 12.5 % (4.1 )%
Botox/Neuromodulator 431.6 396.7 34.9 45.8 (10.9 ) 8.8 % 11.5 % (2.7 )%
Skin Care 74.0 66.4 7.6 7.8 (0.2 ) 11.4 % 11.7 % (0.3 )%
Urologics   9.7     15.0     (5.3 )   (5.3 )   --   (35.3 )% (35.3 )% --
Total Specialty Pharmaceuticals   1,178.5     1,089.7     88.8     124.5     (35.7 ) 8.1 % 11.4 % (3.3 )%
 
Breast Aesthetics 86.1 83.3 2.8 5.9 (3.1 ) 3.4 % 7.1 % (3.7 )%
Obesity Intervention 37.4 49.7 (12.3 ) (11.0 ) (1.3 ) (24.7 )% (22.1 )% (2.6 )%
Facial Aesthetics   89.1     88.4     0.7     4.4     (3.7 ) 0.8 % 5.0 % (4.2 )%
Total Medical Devices   212.6     221.4     (8.8 )   (0.7 )   (8.1 ) (4.0 )% (0.3 )% (3.7 )%
 
Product net sales $ 1,391.1   $ 1,311.1   $ 80.0   $ 123.8   $ (43.8 ) 6.1 % 9.4 % (3.3 )%
 
Selected Product Net Sales (a):
Alphagan P, Alphagan, and

Combigan

$

111.3

$

100.5

$

10.8

$

14.3

$

(3.5

)

10.8

%

14.3

%

(3.5

)%

Lumigan Franchise 152.0 147.0 5.0 12.0 (7.0 ) 3.4 % 8.2 % (4.8 )%
Restasis 198.3 166.1 32.2 32.7 (0.5 ) 19.4 % 19.7 % (0.3 )%
Latisse 23.4 21.8 1.6 1.8 (0.2 ) 7.2 % 7.9 % (0.7 )%
 
Domestic 62.1 % 59.3 %
International 37.9 % 40.7 %
 
ALLERGAN, INC.
Supplemental Non-GAAP Information
(Unaudited)
 
 

  Nine months ended

             

September 30,

 

September 30,

$ change in net sales

Percent change in net sales

2012

2011

Total

Performance

  Currency

  Total

  Performance

Currency

in millions

Eye Care Pharmaceuticals $ 1,986.1 $ 1,861.1 $ 125.0 $ 190.2 $ (65.2 ) 6.7 % 10.2 % (3.5 )%
Botox/Neuromodulator 1,291.7 1,179.6 112.1 140.9 (28.8 ) 9.5 % 11.9 % (2.4 )%
Skin Care 221.0 190.4 30.6 31.1 (0.5 ) 16.1 % 16.3 % (0.2 )%
Urologics   31.8     42.3     (10.5 )   (10.5 )   --   (24.8 )% (24.8 )% --
Total Specialty Pharmaceuticals   3,530.6     3,273.4     257.2     351.7     (94.5 ) 7.9 % 10.7 % (2.8 )%
 
Breast Aesthetics 285.7 262.9 22.8 31.1 (8.3 ) 8.7 % 11.8 % (3.1 )%
Obesity Intervention 122.7 156.2 (33.5 ) (30.5 ) (3.0 ) (21.4 )% (19.5 )% (1.9 )%
Facial Aesthetics   285.2     271.8     13.4     23.7     (10.3 ) 4.9 % 8.7 % (3.8 )%
Total Medical Devices   693.6     690.9     2.7     24.3     (21.6 ) 0.4 % 3.5 % (3.1 )%
 
Product net sales $ 4,224.2   $ 3,964.3   $ 259.9   $ 376.0   $ (116.1 ) 6.6 % 9.5 % (2.9 )%
 
Selected Product Net Sales (a):
Alphagan P, Alphagan, and

Combigan

$

334.7

$

309.2

$

25.5

$

35.1

$

(9.6

)

8.3

%

11.4

%

(3.1

)%

Lumigan Franchise 452.4 452.9 (0.5 ) 17.5 (18.0 ) (0.1 )% 3.9 % (4.0 )%
Restasis 580.0 501.1 78.9 81.3 (2.4 ) 15.7 % 16.2 % (0.5 )%
Latisse 72.4 69.0 3.4 3.9 (0.5 ) 5.0 % 5.6 % (0.6 )%
 
Domestic 60.9 % 59.6 %
International 39.1 % 40.4 %
(a)     Percentage change in selected product net sales is calculated on amounts reported to the nearest whole dollar.
 
ALLERGAN, INC.
Reconciliation of GAAP Diluted Earnings Per Share Expectations
To Non-GAAP Diluted Earnings Per Share Expectations
(Unaudited)
 
  Fourth Quarter 2012
Low   High
 
GAAP diluted earnings per share attributable to Allergan, Inc. stockholders expectations (a) $ 1.12 $ 1.14
 
Amortization of acquired intangible assets   0.06   0.06
Non-GAAP diluted earnings per share expectations $ 1.18 $ 1.20
 
 
Full Year 2012
Low High
 
GAAP diluted earnings per share attributable to Allergan, Inc. stockholders expectations (a) $ 3.64 $ 3.66
 
Expenses from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

0.05

0.05

Aggregate charges for external costs for stockholder derivative litigation associated with the DOJ settlement and other legal contingency expenses

0.03

0.03

Research and development expenses related to upfront licensing fees associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs

 

0.15

 

0.15

Net restructuring charges 0.01 0.01
Amortization of acquired intangible assets 0.24 0.24
Unrealized loss on derivative instruments 0.03 0.03
Change in estimated taxes related to uncertain tax positions included in prior year filings   0.02   0.02
Non-GAAP diluted earnings per share expectations $ 4.17 $ 4.19
(a)     GAAP diluted earnings per share expectations exclude any potential impact of future unrealized gains or losses on derivative instruments, changes in contingent consideration, restructuring charges and stockholder derivative litigation costs related to the 2010 DOJ settlement and other legal contingency expenses that may occur but that are not currently known or determinable.




7 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs